1. Gass JD. Pathogenesis of disciform detachment of theneuroepithelium. Am J Ophthalmol. 1967;63(3):Suppl:1-139.
2. Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Centralserous chorioretinopathy. Acta Ophthalmol. 2008;86(2):126-145.
3. Kaye R, Chandra S, Sheth J, Boon CJF, Sivaprasad S, Lotery A.Central serous chorioretinopathy: An update on risk factors,pathophysiology and imaging modalities. Prog Retin Eye Res.2020;79:100865.
4. Spaide RF, Gemmy Cheung CM, Matsumoto H, et al. Venousoverload choroidopathy: a hypothetical framework for centralserous chorioretinopathy and allied disorders. Prog Retin Eye Res.2022;86:100973.
5. Lehmann M, Bousquet E, Beydoun T, Behar-CohenF. PACHYCHOROID: an inherited condition? Retina.2015;35(1):10-16.
6. Gäckle HC, Lang GE, Freissler KA, Lang GK. [Central serouschorioretinopathy. Clinical, fluorescein angiography anddemographic aspects]. Ophthalmologe. 1998;95(8):529-533.
7. Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. Theincidence of central serous chorioretinopathy in Olmsted County,Minnesota, 1980-2002. Ophthalmology. 2008;115(1):169-173.
8. Spaide RF, Campeas L, Haas A, et al. Central serouschorioretinopathy in younger and older adults. Ophthalmology.1996;103(12):2070-2079; discussion 2079-2080.
9. Tittl MK, Spaide RF, Wong D, et al. Systemic findings associatedwith central serous chorioretinopathy. Am J Ophthalmol.1999;128(1):63-68.
10. Pan CK, Vail D, Bhattacharya J, Cao M, Mruthyunjaya P. Theeffect of obstructive sleep apnea on absolute risk of central serouschorioretinopathy. Am J Ophthalmol. 2020;218:148-155.
11. Tsai DC, Chen SJ, Huang CC, et al. Epidemiology of idiopathiccentral serous chorioretinopathy in Taiwan, 2001-2006: apopulation-based study. PLoS One. 2013;8(6):e66858.
12. Kim YC, Kim SD, Kim KS. A case of idiopathic centralserous chorioretinopathy in a 12-year-old male treated withbevacizumab. Korean J Ophthalmol. 2012;26(5):391-393.
13. Schatz H, Madeira D, Johnson RN, McDonald HR. Central serouschorioretinopathy occurring in patients 60 years of age and older.Ophthalmology. 1992;99(1):63-67.
14. Chan WM, Lim TH, Pece A, Silva R, Yoshimura N. VerteporfinPDT for non-standard indications--a review of current literature.Graefes Arch Clin Exp Ophthalmol. 2010;248(5):613-626.
15. Kunavisarut P, Pathanapitoon K, van Schooneveld M, Rothova A.Chronic central serous chorioretinopathy associated with serousretinal detachment in a series of Asian patients. Ocul ImmunolInflamm. 2009;17(4):269-277.
16. How AC, Koh AH. Angiographic characteristics of acute centralserous chorioretinopathy in an Asian population. Ann Acad MedSingap. 2006;35(2):77-79.
17. Desai UR, Alhalel AA, Campen TJ, Schiffman RM, EdwardsPA, Jacobsen GR. Central serous chorioretinopathy in AfricanAmericans. J Natl Med Assoc. 2003;95(7):553-559.
18. Gilbert CM, Owens SL, Smith PD, Fine SL. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol.1984;68(11):815-820.
19. Baran NV, Gürlü VP, Esgin H. Long-term macular functionin eyes with central serous chorioretinopathy. Clin ExperimentOphthalmol. 2005;33(4):369-372.
20. Ooto S, Tsujikawa A, Mori S, Tamura H, Yamashiro K, YoshimuraN. Thickness of photoreceptor layers in polypoidal choroidalvasculopathy and central serous chorioretinopathy. Graefes ArchClin Exp Ophthalmol. 2010;248:1077-1086.
21. Piccolino FC, De La Longrais RR, Manea M, Cicinelli S. Posteriorcystoid retinal degeneration in central serous chorioretinopathy.Retina. 2008;28(7):1008-1012.
22. Uyama M, Matsunaga H, Matsubara T, Fukushima I, Takahashi K,Nishimura T. Indocyanine green angiography and pathophysiologyof multifocal posterior pigment epitheliopathy. Retina.1999;19(1):12-21.
23. Tuncay FY, Gürelik G. Santral Seröz Koryoretinopati. Retina-Vitreus/Journal of Retina-Vitreous. 2010;18(2).
24. Gemenetzi M, De Salvo G, Lotery A. Central serouschorioretinopathy: an update on pathogenesis and treatment. Eye.2010;24(12):1743-1756.
25. Spaide RF, Ledesma-Gil G, Gemmy Cheung CM. intervortexvenous anastomosis in pachychoroid-related disorders. Retina.2021;41(5):997-1004.
26. Matsumoto H, Hoshino J, Mukai R, et al. Vortex vein anastomosisat the watershed in pachychoroid spectrum diseases. OphthalmolRetina. 2020;4(9):938-945.
27. Imanaga N, Terao N, Nakamine S, et al. Scleral thickness in centralserous chorioretinopathy. Ophthalmol Retina. 2021;5(3):285-291.
28. Sawaguchi S, Terao N, Imanaga N, et al. Scleral Thickness inSteroid-Induced Central Serous Chorioretinopathy. OphthalmolSci. 2022;2(2):100124.
29. Venkatesh P, Chawla R, Tripathy K, Singh HI, Bypareddy R.Scleral resection in chronic central serous chorioretinopathycomplicated by exudative retinal detachment. Eye Vis (Lond).2016;3(1):23.
30. Weenink AC, Borsje RA, Oosterhuis JA. Familial chronic centralserous chorioretinopathy. Ophthalmologica. 2001;215(3):183-187.
31. Miki A, Kondo N, Yanagisawa S, Bessho H, Honda S, Negi A.Common variants in the complement factor H gene confer geneticsusceptibility to central serous chorioretinopathy. Ophthalmology.2014;121(5):1067-1072.
32. de Jong EK, Breukink MB, Schellevis RL, et al. Chronic centralserous chorioretinopathy is associated with genetic variantsimplicated in age-related macular degeneration. Ophthalmology.2015;122(3):562-570.
33. Schubert C, Pryds A, Zeng S, et al. Cadherin 5 is regulatedby corticosteroids and associated with central serouschorioretinopathy. Human mutation. 2014;35(7):859-867.
34. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S, GroupCSCCCS. Risk factors for central serous chorioretinopathy: acase-control study. Ophthalmology. 2004;111(2):244-249.
35. Mansuetta CC, Mason III JO, Swanner J, et al. An associationbetween central serous chorioretinopathy and gastroesophagealreflux disease. Am J Ophthalmol. 2004;137(6):1096-1100.
36. Ahnoux-Zabsonre A, Quaranta M, Mauget-Faysse M. Prevalenceof Helicobacter pylori in central serous chorioretinopathy anddiffuse retinal epitheliopathy: a complementary study. J FrancaisD'ophtalmologie. 2004;27(10):1129-1133.
37. Carvalho-Recchia CA, Yannuzzi LA, Negrão S, et al.Corticosteroids and central serous chorioretinopathy.Ophthalmology. 2002;109(10):1834-1837.
38. Pizzimenti JJ, Daniel KP. Central serous chorioretinopathy afterepidural steroid injection. Pharmacotherapy: J Hum PharmacolDrug Therapy. 2005;25(8):1141-1146.
39. Kassam A-A, White W, Ling RH, Kitson JB. Loss of visual acuitydue to central serous retinopathy after steroid injection into theshoulder bursa. J Shoulder Elbow Surg. 2011;20(4):e5-e6.
40. Ezra N, Taban M, Behroozan D. Central serous chorioretinopathyassociated with topical corticosteroids in a patient with psoriasis.J Drugs Dermatol: JDD. 2011;10(8):918-921.
41. Baumal CR, Martidis A, Truong SN. Central serouschorioretinopathy associated with periocular corticosteroidinjection treatment for HLA-B27-associated iritis. ArchOphthalmol. 2004;122(6):926-928.
42. Ji Y, Li M, Zhang X, Peng Y, Wen F. Poor sleep quality is therisk factor for central serous chorioretinopathy. J Ophthalmol.2018;2018:9450297.
43. Tien PT, Lai CY, Lin CJ, et al. Increased risk of central serouschorioretinopathy among patients with nonorganic sleepdisturbance. J Ophthalmol. 2020;2020:1712503.
44. Jiang MS, Xu XL, Yang T, Li F, Zhang XD. Comparison ofchoroidal thickness in preeclamptic, healthy pregnant, andnonpregnant women: a systematic review and meta-analysis.Ophthalmic Res. 2019;62(1):1-10.
45. Mayo GL, Tolentino MJ. Images in clinical medicine. Centralserous chorioretinopathy in pregnancy. N Engl J Med.2005;353(7):e6.
46. Asensio-Sánchez VM, Rodríguez-Delgado B, García-HerreroE, Cabo-Vaquera V, García-Loygorri C. [Central serouschorioretinopathy as an extradigestive manifestation ofHelicobacter pylori gastric infection]. Arch Soc Esp Oftalmol. Mar2008;83(3):177-182.
47. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S. Riskfactors for central serous chorioretinopathy: a case-control study.Ophthalmology. 2004;111(2):244-249.
48. Karadağ MF. A new potential risk factor for central serouschorioretinopathy: blood pressure variability. Eye (Lond).2021;35(8):2190-2195.
49. Cassel GH, Brown GC, Annesley WH. Central serouschorioretinopathy: a seasonal variation? Br J Ophthalmol.1984;68(10):724-726.
50. Ersoz MG, Arf S, Hocaoglu M, Sayman Muslubas I, KaracorluM. Patient characteristics and risk factors for central serouschorioretinopathy: an analysis of 811 patients. Br J Ophthalmol.2019;103(6):725-729.
51. Yzer S, Fung AT, Barbazetto I, Yannuzzi LA, Freund KB. Centralserous chorioretinopathy in myopic patients. Arch Ophthalmol.2012;130(10):1339-1340.
52. Hunter RG. Epigenetic effects of stress and corticosteroids in thebrain. Front Cell Neurosci. 2012;6:18.
53. Chen S-N, Chen Y-C, Lian I. Increased risk of coronary heartdisease in male patients with central serous chorioretinopathy:results of a population-based cohort study. Br J Ophthalmol.2014;98(1):110-114.
54. Tsai D-C, Huang C-C, Chen S-J, et al. Central serouschorioretinopathy and risk of ischaemic stroke: a population-based cohort study. Br J Ophthalmol. 2012;96(12):1484-1488.
55. Tsai DC, Huang CC, Chen SJ, et al. Increased risk oferectile dysfunction among males with central serouschorioretinopathy-a retrospective cohort study. ActaOphthalmologica. 2013;91(7):666-671.
56. Tewari HK, Gadia R, Kumar D, Venkatesh P, Garg SP.Sympathetic-parasympathetic activity and reactivity in centralserous chorioretinopathy: a case-control study. InvestigativeOphthalmol Visual Sci. 2006;47(8):3474-3478.
57. Pierce KK, Lane RG. Central serous chorioretinopathy associatedwith the use of ephedra. Retinal Cases Brief Rep. 2009;3(4):376-378.
58. Aliferis K, Petropoulos I, Farpour B, Matter M, Safran A. Shouldcentral serous chorioretinopathy be added to the list of ocularside effects of phosphodiesterase 5 inhibitors? Ophthalmologica.2012;227(2):85-89.
59. Vance SK, Imamura Y, Freund KB. The effects of sildenafil citrateon choroidal thickness as determined by enhanced depth imagingoptical coherence tomography. Retina. 2011;31(2):332-335.
60. Bouzas EA, Karadimas P, Pournaras CJ. Central serouschorioretinopathy and glucocorticoids. Surv Ophthalmol.2002;47(5):431-448.
61. Ge G, Zhang Y, Zhang Y, Xu Z, Zhang M. Corticosteroids usageand central serous chorioretinopathy: a meta-analysis. GraefesArch Clin Exp Ophthalmol. 2020;258(1):71-77.
62. Imasawa M, Ohshiro T, Gotoh T, Imai M, Iijima H. Centralserous chorioretinopathy following vitrectomy with intravitrealtriamcinolone acetonide for diabetic macular oedema. ActaOphthalmologica Scandinavica. 2005;83(1):132-133.
63. Khairallah M, Kahloun R, Tugal-Tutkun I. Central serouschorioretinopathy, corticosteroids, and uveitis. Ocular ImmunolInflammation. 2012;20(2):76-85.
64. Han JM, Hwang J-M, Kim JS, Park KH, Woo SJ. Changes inchoroidal thickness after systemic administration of high-dosecorticosteroids: a pilot study. Invest Ophthalmol Visual Sci.2014;55(1):440-445.
65. Haimovici R, Rumelt S, Melby J. Endocrine abnormalities inpatients with central serous chorioretinopathy. Ophthalmology.2003;110(4):698-703.
66. Yannuzzi LA. Type-A behavior and central serouschorioretinopathy. Retina (Philadelphia, Pa.). 1987;7(2):111-131.
67. Yannuzzi LA. Type A behavior and central serouschorioretinopathy. Trans Am Ophthalmol Soc. 1986;84:799-845.
68. Conrad R, Weber NF, Lehnert M, Holz FG, Liedtke R, Eter N.Alexithymia and emotional distress in patients with centralserous chorioretinopathy. Psychosomatics. 2007;48(6):489-495.
69. Nattis A. Update on the Diagnosis and Treatment of CSC. RetinalPhysician, Volume: 12, Issue: October 2015, page(s): 18-21